Compare AMRX & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMRX | HSAI |
|---|---|---|
| Founded | 2002 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2018 | 2021 |
| Metric | AMRX | HSAI |
|---|---|---|
| Price | $13.05 | $24.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $14.75 | ★ $31.58 |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 05-01-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.89 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.48 | $46.32 |
| Revenue Next Year | $7.13 | $41.24 |
| P/E Ratio | ★ $59.61 | $61.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.01 | $10.62 |
| 52 Week High | $15.42 | $30.85 |
| Indicator | AMRX | HSAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 58.17 |
| Support Level | $12.50 | $22.35 |
| Resistance Level | $13.54 | $28.64 |
| Average True Range (ATR) | 0.33 | 0.95 |
| MACD | 0.15 | 0.57 |
| Stochastic Oscillator | 87.42 | 96.21 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.